Results from early reports underestimated the functions of this co-mutation in NSCLC, and emerging evidences suggest that EGFR mutation systematically accompanied the TP53 mutation in lung AC, thus affecting resistance to EGFR TKIs therapy and poor prognosis, which is consistent with our study. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.